BioLineRx Ltd. (BLRX)
NASDAQ·Healthcare·Biotechnology
$2.69
+20.41%
Mkt Cap $11.49M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 23, 2026 | $514.00K | $514.00K | +0.00% | -$0.50 | -$0.34 | +32.00% | — | — |
| Q4 2025 Nov 24, 2025 | $670.00K | $427.00K | -36.27% | -$0.41 | -$0.22 | +46.34% | — | — |
| Q3 2025 Aug 14, 2025 | $776.67K | $304.00K | -60.86% | -$0.35 | -$1.00 | -185.71% | — | — |
| Q2 2025 May 27, 2025 | $1.83M | $255.00K | -86.04% | -$0.84 | $1.39 | +265.48% | — | — |
| Q1 2025 Mar 25, 2025 | $7.72M | $11.75M | +52.22% | -$4.20 | $6.00 | +242.86% | — | — |
| Q4 2024 Nov 25, 2024 | $5.23M | $4.94M | -5.51% | -$0.05 | -$2.80 | -5500.00% | — | — |
| Q3 2024 Aug 15, 2024 | $3.93M | $5.39M | +37.23% | -$0.14 | $0.40 | +385.71% | — | — |
| Q2 2024 May 28, 2024 | $6.80M | $6.86M | +0.81% | -$0.29 | -$0.01 | +96.55% | — | — |
| Q1 2024 Mar 26, 2024 | $3.00M | $4.80M | +60.00% | -$0.22 | -$0.15 | +31.82% | — | — |
| Q4 2023 Nov 20, 2023 | — | — | — | -$7.20 | -$12.00 | -66.67% | — | — |
| Q3 2023 Aug 30, 2023 | — | — | — | -$6.40 | -$12.00 | -87.50% | — | — |
| Q2 2023 May 24, 2023 | — | — | — | -$5.60 | -$6.00 | -7.14% | — | — |
| Q1 2023 Mar 22, 2023 | — | — | — | -$5.60 | -$3.60 | +35.71% | — | — |
| Q4 2022 Nov 15, 2022 | — | — | — | -$6.40 | -$6.00 | +6.25% | — | — |
| Q3 2022 Aug 16, 2022 | — | — | — | -$5.60 | -$6.40 | -14.29% | — | — |
| Q2 2022 May 11, 2022 | — | — | — | -$6.00 | -$4.00 | +33.33% | — | — |
| Q1 2022 Mar 16, 2022 | — | — | — | -$5.60 | -$3.20 | +42.86% | — | — |
| Q4 2021 Nov 18, 2021 | — | — | — | -$5.20 | -$9.20 | -76.92% | — | — |
| Q3 2021 Aug 18, 2021 | — | — | — | -$4.80 | -$6.00 | -25.00% | — | — |
| Q2 2021 May 26, 2021 | — | — | — | -$6.00 | -$10.80 | -80.00% | — | — |